More stable and reliable pharmacokinetics with preprandial administration of cyclosporine compared with postprandial administration in patients with refractory nephrotic syndrome

Pharmacotherapy

Volumn 25, Issue 1, 2005, Pages 52-58

  Kusaba, Tetsuro ^a   Konno, Yusuke ^a   Hatta, Shigeo ^a   Fujino, Tomoya ^a   Yasuda, Takashi ^a   Miura, Hiroshi ^a   Sasaki, Hiroyo ^a   Okabayashi, Jun ^a   Murao, Mei ^a   Sakurada, Tsutomu ^a   Imai, Goro ^a   Shirai, Sayuri ^a   Kuboshima, Shingo ^a   Shima, Yoshinori ^a   Ogimoto, Goichi ^a   Sato, Takeo ^a   Masuhara, Keisou ^a   Kimura, Kenjiro ^a  

^a NONE

Author keywords

Absorption profile; Cyclosporine; Neoral; Nephrotic syndrome; Pharmacokinetics; Postprandial administration; Preprandial administration

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG ABSORPTION; FEMALE; HUMAN; JAPAN; MALE; NEPHROTIC SYNDROME; PROSPECTIVE STUDY; RELIABILITY; UNIVERSITY HOSPITAL;

ABSORPTION; AREA UNDER CURVE; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FASTING; HOSPITALS, UNIVERSITY; HUMANS; MIDDLE AGED; NEPHROTIC SYNDROME; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 19944429269     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.1.52.55617     Document Type: Article

References (21)

1. Iida HNT, Sakai N, Aoki S. Effect of cyclosporin therapy on idiopathic membranous nephropathy presented with refractory nephrotic syndrome. Clin Exp Nephrol 2000;4:81-5.
2. Meyrier A, Noel LH, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative group of the societe de nephrologie. Kidney Int 1994;45:1446-56.
3. Cattran DC, Appel GB, Hebert LA, et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001;59:1484-90.
4. Matsumoto H, Nakao T, Okada T, et al. Initial remission-inducing effect of very low-dose cyclosporin monotherapy for minimal-change nephrotic syndrome in Japanese adults. Clin Nephrol 2001;55:143-8.
5. Kung L, Batiuk TD, Palomo-Pinon S, Noujaim J, Helms LM, Halloran PF. Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. Am J Transplant 2001;1:325-33.
6. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999;68:1356-61.
7. Halloran PF. Calcineurin inhibition-relationship to cyclosporin blood concentration. Focus Med 1998;13:15-18.
8. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 2001;72:1024-32.
9. Internation Neoral Renal Transplantation Study Group. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2002;2:157-66.
10. Rainiene T, Papinigiene L, Laurinavicius A. Nephrotoxicity of cyclosporin A after kidney transplantation [in Lithuanian]. Mediclna (Kaunas) 2003;39(suppl 1):161-5.
11. Lindholm A, Henricsson S, Dahlqvist R. The effect of food and bile acid administration on the relative bioavailability of cyclosporin. Br J Clin Pharmacol 1990;29:541-8.
12. max) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8). Transplantation 1999;67:1133-7.
13. Mueller EA, Kovarik JM, van Bree JB, Tetzloff W, Grevel J, Kutz K. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994;11:301-4.
14. Mraz W, Muller C, Molnar B, Knedel M. Analysis of cyclosporin A (CsA) concentrations by fluorescence polarization immunoassay (FPIA): comparison with radio immunoassay (RIA) and liquid chromatography (HPLC). Transplant Proc 1989;21(1 pt 1):885-7.
15. Dalere GM, Lum BL, Cooney GF, Wong-Chin M. Comparison of three methods for cyclosporine area under the curve monitoring calculations. Ther Drug Monit 1995;17:305-7.
16. 0-4 monitoring in maintenance renal transplant patients. Transplant Proc 2001;33:3128-30.
17. Mahalati K, Belitsky P, West K, et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol 2001;12:828-33.
18. Belitsky P, Dunn S, Johnston A, Levy G. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients. Clin Pharmacokinet 2000;39:117-25.
19. Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Aspeslet L, Metrakos P. Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 1998;66:1621-7.
20. 2 in liver transplant recipients. Transplant Proc 2001;33:3089-91.
21. 2). Transplantation 2002;73:953-9.